Piramal in double US expansion

Indian CDMO Piramal Pharma is to spend $90 million on brownfield expansions at two US sites. The company said that these both come in response to ongoing demand from US customers and the trend towards US onshoring of drug supply. They are also expected to generate greater opportunities for integrated antibody-drug conjugates (ADC) projects.

At the former Ash Stevens site in Riverview, Michigan (pictured), Piramal is adding a commercial-scale suite to make payload-linkers for ADCs and other bioconjugate drugs to complement existing HPAPI manufacture. This is expected to be operational before the end of 2025. 

The company will also add commercial-scale manufacturing for injectable drug products at Lexington, Kentucky. Key features include a new filling line, two commercial-size lyophilisers, a special capping machine and an external vial washer. This is expected to be completed and online by late 2027.

Since its inception, Piramal Pharma has invested $570 million in its US drug development and manufacturing capabilities. The US is its largest market. In all, about 750 people work across its network of sites there, which also include drug product facilities at Sellersville and Bethlehem, both in Pennsylvania.